Aplaviroc

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aplaviroc
Systematic (IUPAC) name
4-(4-{[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo- 1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 461023-63-2 YesY
ATC code None
PubChem CID 3001322
ChemSpider 2272720 YesY
UNII 98B425P30V YesY
KEGG D06557 YesY
Chemical data
Formula C33H43N3O6 
Mol. mass 577.711 g/mol
 YesY (what is this?)  (verify)

Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor developed for the treatment of HIV infection.[1][2] It is developed by GlaxoSmithKline

In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns.[3][4] Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development;[5] the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations.[6]

See also [edit]

References [edit]

Further reading [edit]

  • Horster S, Goebel FD (April 2006). "Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge". Infection 34 (2): 110–3. doi:10.1007/s15010-006-6206-1. PMID 16703305.